EP4140989C0 - 2-arylthiazolderivat oder salz davon, herstellungsverfahren dafür und pharmazeutische zusammensetzung damit - Google Patents
2-arylthiazolderivat oder salz davon, herstellungsverfahren dafür und pharmazeutische zusammensetzung damitInfo
- Publication number
- EP4140989C0 EP4140989C0 EP21792031.3A EP21792031A EP4140989C0 EP 4140989 C0 EP4140989 C0 EP 4140989C0 EP 21792031 A EP21792031 A EP 21792031A EP 4140989 C0 EP4140989 C0 EP 4140989C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- salt
- pharmaceutical composition
- manufacturing process
- arylthiazole derivative
- arylthiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200048262A KR102871918B1 (ko) | 2020-04-21 | 2020-04-21 | 신규의 2-아릴티아졸 유도체 또는 이의 염, 이의 제조방법, 및 이를 함유하는 약학 조성물 |
| PCT/KR2021/000578 WO2021215624A1 (ko) | 2020-04-21 | 2021-01-15 | 신규의 2-아릴티아졸 유도체 또는 이의 염, 이의 제조방법, 및 이를 함유하는 약학 조성물 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| EP4140989A1 EP4140989A1 (de) | 2023-03-01 |
| EP4140989A4 EP4140989A4 (de) | 2023-10-18 |
| EP4140989C0 true EP4140989C0 (de) | 2024-07-17 |
| EP4140989B1 EP4140989B1 (de) | 2024-07-17 |
Family
ID=78231501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21792031.3A Active EP4140989B1 (de) | 2020-04-21 | 2021-01-15 | 2-arylthiazolderivat oder salz davon, herstellungsverfahren dafür und pharmazeutische zusammensetzung damit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12503451B2 (de) |
| EP (1) | EP4140989B1 (de) |
| JP (1) | JP7692002B2 (de) |
| KR (1) | KR102871918B1 (de) |
| CN (1) | CN115667233B (de) |
| AU (1) | AU2021261570A1 (de) |
| CA (1) | CA3176088A1 (de) |
| ES (1) | ES2987881T3 (de) |
| WO (1) | WO2021215624A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4378932A1 (de) * | 2022-11-30 | 2024-06-05 | Universität Bern | Cd93 inhibitoren |
| CN119528900A (zh) * | 2024-08-08 | 2025-02-28 | 河南科技大学 | 具有抗肝癌活性的甲基噻唑衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002105067A (ja) * | 2000-09-28 | 2002-04-10 | Teijin Ltd | ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
| EP1848428A4 (de) * | 2005-02-18 | 2012-04-18 | Neurogen Corp | Thiazolamide, imidazolamide und verwandte analoga |
| WO2006103045A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| JP2010037337A (ja) * | 2008-07-09 | 2010-02-18 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| WO2010128163A2 (en) * | 2009-05-08 | 2010-11-11 | Pike Pharma Gmbh | Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication |
| WO2012073259A1 (en) * | 2010-12-02 | 2012-06-07 | Indoco Remedies Limited | Novel process for the preparation of febuxostat |
| KR20120131401A (ko) | 2011-05-25 | 2012-12-05 | 울산대학교 산학협력단 | 자가포식작용 촉진제의 신규 용도 |
| KR101731908B1 (ko) | 2015-08-18 | 2017-05-11 | 서울대학교산학협력단 | p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료 |
| KR102100470B1 (ko) | 2015-08-21 | 2020-04-13 | (주)오토파지사이언스 | 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 |
| KR101915016B1 (ko) * | 2016-07-12 | 2018-11-06 | 연세대학교 산학협력단 | 자가포식 향상물질 및 그 용도 |
| CN110066258A (zh) | 2018-01-23 | 2019-07-30 | 湘北威尔曼制药股份有限公司 | 噻唑-5-甲酸衍生物及其制备方法与应用 |
| CA3106968A1 (en) * | 2018-07-20 | 2020-01-23 | Hexapharmatec Co., Ltd. | Novel catechol derivatives or salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
-
2020
- 2020-04-21 KR KR1020200048262A patent/KR102871918B1/ko active Active
-
2021
- 2021-01-15 ES ES21792031T patent/ES2987881T3/es active Active
- 2021-01-15 US US17/996,544 patent/US12503451B2/en active Active
- 2021-01-15 JP JP2022564122A patent/JP7692002B2/ja active Active
- 2021-01-15 CA CA3176088A patent/CA3176088A1/en active Pending
- 2021-01-15 EP EP21792031.3A patent/EP4140989B1/de active Active
- 2021-01-15 WO PCT/KR2021/000578 patent/WO2021215624A1/ko not_active Ceased
- 2021-01-15 CN CN202180040070.8A patent/CN115667233B/zh active Active
- 2021-01-15 AU AU2021261570A patent/AU2021261570A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021261570A1 (en) | 2022-12-08 |
| US12503451B2 (en) | 2025-12-23 |
| KR102871918B1 (ko) | 2025-10-17 |
| EP4140989A4 (de) | 2023-10-18 |
| US20230219908A1 (en) | 2023-07-13 |
| EP4140989A1 (de) | 2023-03-01 |
| CN115667233B (zh) | 2024-05-24 |
| CA3176088A1 (en) | 2021-10-28 |
| ES2987881T3 (es) | 2024-11-18 |
| KR20210130016A (ko) | 2021-10-29 |
| WO2021215624A1 (ko) | 2021-10-28 |
| CN115667233A (zh) | 2023-01-31 |
| JP2023523417A (ja) | 2023-06-05 |
| JP7692002B2 (ja) | 2025-06-12 |
| EP4140989B1 (de) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4053152A4 (de) | Keratin bd-13, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon | |
| EP4431513A4 (de) | Polycyclisches carbamoylpyridonderivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung daraus | |
| WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
| EP3750886A4 (de) | Tetrahydroisochinolinverbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung damit und verwendung davon | |
| EP4610261A4 (de) | Stickstoffhaltige heterocyclische verbindung, pharmazeutisch unbedenkliches salz davon, herstellungsverfahren dafür und verwendung davon | |
| EP4140989C0 (de) | 2-arylthiazolderivat oder salz davon, herstellungsverfahren dafür und pharmazeutische zusammensetzung damit | |
| EP4219463C0 (de) | Terpyridindiketonverbindung oder salz davon, herstellungsverfahren dafür und anwendung davon | |
| EP4310093A4 (de) | Aminosäurederivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung zur behandlung von hepatitis damit | |
| EP4110781A4 (de) | 1,3,4oxadiazolderivatverbindungen als histondeacetylase-6-hemmer und pharmazeutische zusammensetzung damit | |
| EP4053159A4 (de) | Keratin bd-6, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon | |
| EP4385988A4 (de) | Substituiertes triazolderivat, herstellungsverfahren dafür, pharmazeutische zusammensetzung davon und verwendung davon | |
| EP4452525A4 (de) | Teilchenverbesserung von verbundwerkstoffen mit keramischer matrix, herstellungsverfahren dafür und artikel damit | |
| EP4226777A4 (de) | Nikotinfolie und aerosolerzeugungsartikel damit | |
| EP4400505A4 (de) | Peptid-harnstoff-derivat, pharmazeutische zusammensetzung damit und anwendung davon | |
| EP4501925A4 (de) | Stickstoffhaltige heterocyclische verbindung, herstellungsverfahren dafür und pharmazeutische anwendung davon | |
| EP4342900A4 (de) | Sesquiterpenderivate sowie pharmazeutische zusammensetzungen daraus, herstellungsverfahren dafür und verwendung davon | |
| EP4353709A4 (de) | Pharmazeutisches salz von fingolimod, herstellungsverfahren dafür, pharmazeutische zusammensetzung damit und verwendung davon | |
| EP4393512A4 (de) | Zusammensetzung für medizinische tablette, damit hergestellte medizinische tablette und herstellungsverfahren dafür | |
| EP4382514A4 (de) | Pyrimidinderivat, verfahren zur herstellung davon und pharmazeutische zusammensetzung zur prävention oder behandlung von krebs damit als wirkstoff | |
| EP4361259A4 (de) | Neue beta-carotin-15,15-oxygenase-variante und retinoidherstellungsverfahren damit | |
| EP4286371A4 (de) | Pyrazolamidderivat, herstellungsverfahren dafür und anwendung davon | |
| EP4098271A4 (de) | Pharmazeutische zusammensetzung zum vorbeugen oder behandeln von krebs, mit weissella cibaria wikim28 als wirkstoff | |
| EP4578849A4 (de) | Neuartiges piperazinderivat oder salz davon und pharmazeutische zusammensetzung | |
| EP4345096A4 (de) | Piperidinderivat und pharmazeutische zusammensetzung davon, herstellungsverfahren dafür und verwendung davon | |
| EP3778576C0 (de) | 2-cyanopyrimidin-4-ylcarbamat- oder harnstoffderivat oder salz davon und pharmazeutische zusammensetzung damit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20221114 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07D0277280000 Ipc: C07D0277560000 Ref document number: 602021015930 Country of ref document: DE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20230915 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20230911BHEP Ipc: A61P 1/16 20060101ALI20230911BHEP Ipc: A61P 25/28 20060101ALI20230911BHEP Ipc: A61P 25/16 20060101ALI20230911BHEP Ipc: A61K 31/5377 20060101ALI20230911BHEP Ipc: A61K 31/454 20060101ALI20230911BHEP Ipc: A61K 31/551 20060101ALI20230911BHEP Ipc: A61K 31/426 20060101ALI20230911BHEP Ipc: C07D 417/12 20060101ALI20230911BHEP Ipc: C07D 417/06 20060101ALI20230911BHEP Ipc: C07D 277/56 20060101AFI20230911BHEP |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20231031BHEP Ipc: A61P 1/16 20060101ALI20231031BHEP Ipc: A61P 25/28 20060101ALI20231031BHEP Ipc: A61P 25/16 20060101ALI20231031BHEP Ipc: A61K 31/5377 20060101ALI20231031BHEP Ipc: A61K 31/454 20060101ALI20231031BHEP Ipc: A61K 31/551 20060101ALI20231031BHEP Ipc: A61K 31/426 20060101ALI20231031BHEP Ipc: C07D 417/12 20060101ALI20231031BHEP Ipc: C07D 417/06 20060101ALI20231031BHEP Ipc: C07D 277/56 20060101AFI20231031BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240205 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021015930 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20240813 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240826 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2987881 Country of ref document: ES Kind code of ref document: T3 Effective date: 20241118 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 5 Effective date: 20241205 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241017 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241018 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20241121 Year of fee payment: 5 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241117 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241017 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241017 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241017 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241117 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241018 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20250206 Year of fee payment: 5 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20250422 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240717 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250131 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250115 |